Zumrad (sasanlimab)
- Region
- 🇪🇺 EU
- Active substance
- sasanlimab
- Company
- Pfizer Europe MA EEIG
- Status
- Application withdrawn
- Therapeutic area
- Urinary Bladder Neoplasms
- Application
- EMEA/H/C/006641
- ATC
- L01FF
- Official record
- www.ema.europa.eu
Indication
Treatment of bladder cancer in adults indicated for the treatment of adult indicated for treatement of bladder cancer.
Regulatory milestones
No milestones recorded in the last year.
Follow Zumrad
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.